[Ineffectiveness of diltiazem in Duchenne muscular dystrophy: a placebo-controlled double-blind study].
In a randomized double-blind study the clinical efficacy of the calcium channel blocker, diltiazem was compared to that of a placebo on the clinical course of Duchenne's dystrophy (DMD) over a 12-month period. Altogether 30 patients, mostly in an advanced state of the disease, were evaluated. The 17 patients in the diltiazem group received 90-360 mg diltiazem per day according to their body weight; the 13 patients of the placebo group received the equivalent amount of a placebo. No significant difference was detected between the two groups regarding muscular power, muscle state, muscular functional ability (Vignos), serum myoglobin and serum creative phosphokinase.
Toifl
K
K
Universitätsklinik für Neuropsychiatrie für Kinder und Jugendliche, Wien.
Presterl
E
E
Graninger
W
W
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003402:Creatine Kinase / Q000097:blood; D004110:Diltiazem / Q000627:therapeutic use*; D004311:Double-Blind Method; D004573:Electrolytes / Q000097:blood; D006801:Humans; D008134:Long-Term Care; D009119:Muscle Contraction / Q000187:drug effects; D009136:Muscular Dystrophies / Q000097:blood / Q000188:drug therapy*; D009211:Myoglobin / Q000097:blood; D016059:Range of Motion, Articular / Q000187:drug effects
D004573:Electrolytes; D009211:Myoglobin; D003402:Creatine Kinase; D004110:Diltiazem
Fehlende Wirksamkeit von Diltiazem bei Duchenne-Muskeldystrophie: eine placebo-kontrollierte Doppelblindstudie.